TABLE 3.
Overall survival (OS): univariate and multivariate analyses in the bendamustine and rituximab (BR) cohort
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age > 65 vs ≤ 65 years | 3.95 (0.53‐29.50) | 0.18 | ||
| Binet B‐C vs Binet A | 2.42 (0.79‐7.41) | 0.12 | ||
| β2 microglobulin ≥ 3·0.5 vs < 3.5 mg/L | 4.11 (0.55‐30.92) | 0.17 | ||
| IGHV unmutated vs mutated | 0.81 (0.22‐3.05) | 0.76 | ||
| 17p‐ and/or TP53 mutated yes vs no | 6.14 (2.08‐18.13) | <0.01 | 4.47 (1.37‐14.56) | 0.01 |
| NR vs CR or PR | 8.43 (3.52‐20.19) | <0.01 | 15.21 (5.72‐40.74) | <0.01 |
| Gender female vs male | 0.68 (0.29‐1.64) | 0.39 | ||
| ECOG 0 vs 1 | 2.28 (0.79‐6.59) | 0.13 | ||
| ECOG 0 vs ≥ 2 | 4.90 (1.48‐16.19) | 0.01 | ||
| Comorbidities 0‐1 vs ≥ 2 | 1.79 (0.60‐5.29) | 0.29 | ||
| Creatinine clearance ≤ 70 vs > 70 mL/min | 3.02 (1.01‐9.09) | 0.05 | ||
| no‐aberrations vs 13q | 0.74 (0.12‐4.45) | 0.74 | ||
| 11q‐ vs 13q | 3.18 (0.52‐19.37) | 0.21 | ||
| +12 vs 13q | 3.88 (0.90‐16.71) | 0.07 | ||
| 17p‐ vs 13q | 11.29 (2.08‐61.14) | <0.01 | ||
Legend: NR, no response; CR, complete response; PR, partial response.